よむ、つかう、まなぶ。
参考資料4 有効性評価に基づく子宮頸がん検診ガイドライン更新版2020年３月31日 (68 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_25869.html |
| 出典情報 | がん検診のあり方に関する検討会（第35回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
91) Zheng B, Li Z, Griffith CC, Yan S, Chen C, Ding X, Liang X, Yang H, Zhao C. Prior
high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's
largest CAP-certified laboratory. Cancer Cytopathol. 2015; 123(7): 428-434.
92) Tao X, Griffith CC, Zhou X, Wang Z, Yan Y, Li Z, Zhao C. History of high-risk HPV
and Pap test results in a large cohort of patients with invasive cervical carcinoma:
experience from the largest women's hospital in China. Cancer Cytopathol. 2015; 123(7):
421-427.
93) Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer
screening results among 256,648 women in multiple clinical practices. Cancer
Cytopathol. 2015; 123(5): 282-288.
94) Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS,
Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE. Relative performance of
HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst.
2018; 110(5): 501-508.
95) Watson M, Benard V, Flagg EW. Assessment of trends in cervical cancer screening
rates using healthcare claims data: United States, 2003―2014. Prev Med Rep. 2018; 9:
124-130.
high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's
largest CAP-certified laboratory. Cancer Cytopathol. 2015; 123(7): 428-434.
92) Tao X, Griffith CC, Zhou X, Wang Z, Yan Y, Li Z, Zhao C. History of high-risk HPV
and Pap test results in a large cohort of patients with invasive cervical carcinoma:
experience from the largest women's hospital in China. Cancer Cytopathol. 2015; 123(7):
421-427.
93) Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer
screening results among 256,648 women in multiple clinical practices. Cancer
Cytopathol. 2015; 123(5): 282-288.
94) Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS,
Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE. Relative performance of
HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst.
2018; 110(5): 501-508.
95) Watson M, Benard V, Flagg EW. Assessment of trends in cervical cancer screening
rates using healthcare claims data: United States, 2003―2014. Prev Med Rep. 2018; 9:
124-130.